The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
April 10, 2014
-
BUSINESS Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
April 9, 2014
-
BUSINESS Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.
April 8, 2014
-
BUSINESS India’s Sun Pharma to Acquire Ranbaxy via Equity Swap Deal, Taking Ranbaxy Off Daiichi Sankyo Scorecard
April 7, 2014
-
BUSINESS Novartis Replaces Japan Unit Head amid SIGN Trial Probe
April 4, 2014
-
BUSINESS Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
-
BUSINESS 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments
April 2, 2014
-
REGULATORY Lower House Panels to Begin Deliberations on Japanese NIH-Related Bills
April 1, 2014
-
BUSINESS Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
-
BUSINESS Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
-
BUSINESS Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
-
ORGANIZATION JPMA to Ban Drug Makers from Giving Grants for Clinical Research on Own Products
March 28, 2014
-
ORGANIZATION Funding Disclosures by 5 More FPMAJ Trade Groups to Get Underway in FY2014
March 27, 2014
-
BUSINESS Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho
March 26, 2014
-
BUSINESS Novartis Will Not Sell Rasilamlo Blood Pressure Drug in Japan
March 26, 2014
-
REGULATORY MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates
March 25, 2014
-
ACADEMIA Experts Disagree over Full-Introduction of GCP at JCS Meeting
March 24, 2014
-
ORGANIZATION JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
-
REGULATORY MHLW to Set Rules on OTC Switching of Diagnostics This Year
March 20, 2014
-
BUSINESS Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
ページ
As Japan moves into elaborate discussions on the potential reform of its cost-effectiveness assessment (CEA) in FY2024, members of a…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
The Japanese government on September 12 approved Moderna’s updated monovalent COVID-19 vaccine directed at the Omicron XBB.1.5 strain, following its…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…